Trial Profile
A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bone metastases
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare
- 29 Jul 2020 Status changed from completed to discontinued due to lower than expected recruitment since the start of study.
- 04 Sep 2019 Status changed from active, no longer recruiting to completed.
- 05 Aug 2019 Planned End Date changed from 26 Jul 2019 to 13 Aug 2019.